Cholangiocarcinoma News

Patient Advocacy Initiatives of the Cholangiocarcinoma Foundation

August 2020, Vol 1, No 1

During the 2020 Cholangiocarcinoma Foundation (CCF) Annual Conference, Melinda Bachini, Director of Advocacy for the foundation, presented an update on the foundation’s advocacy activities and initiatives toward promotion of the cholangiocarcinoma (CCA) community.

The aim of the CCF’s advocacy group is to enhance in-depth knowledge regarding CCA, provide educational and emotional support for the CCA community of patients and caregivers, and influence clinical research and healthcare delivery in pursuit of improving outcomes for patients with CCA, while channeling the strong emotional culture of patients and caregivers into working toward meeting CCF’s community objectives.

A Team of Volunteers

Ms Bachini has a team of dedicated advocate volunteers who often have daily interactions with patients and caregivers via the phone and e-mail. Her team of volunteers provides referral support for patients with CCA and offers caregivers guidance and support for their own needs. Ms Bachini’s team is also available to help patients find clinical trials as well as CCA experts and treatment facilities specializing in CCA care.

In addition, the advocacy group has a research advocacy committee team composed of 30 members. The members use social media platforms and other electronic media to interact with patients to provide them with timely information on new research findings.

Team representatives participate on patient advisory boards for academic and industry institutions and have a strong presence at oncology conferences. The committee members are kept up to date on the latest research findings related to CCA via monthly webinars and teleconferences.

Ms Bachini introduced a new initiative that her team has been working on in the United States. Her group has held 5 half-day regional CCA symposia at academic institutions in 2020. More than 300 attendees participated in these regional symposia. Patients, caregivers, physicians, and researchers used the opportunity to meet and network with one another. A CCA expert is brought in to present the latest clinical data and discoveries from research.

Other new actions that Ms Bachini is driving include monthly patient and caregiver support group meetings, and twice-monthly educational webinars on various CCA-related topics. The surveys that patients and caregivers are submitting back to CCF will provide the material for topics to address in upcoming webinars.

A New Patient Registry

In the future, Ms Bachini would like to provide robust patient services by expanding the research advocacy efforts to align with CCF’s strategic plan. In addition, other plans that are in the works include:

  • Launching a new patient registry, which will help with patient data collection, recruit patients for clinical trials, or monitor outcomes and best practices; using the existing partnership with Ciitizen, a health technology platform, to provide opportunities for research, finding clinical trials for patients, and helping patients collect their medical records at no cost to them
  • Continuing to invest in patient educational resources, including a nutritional and diet resource by the end of the year; preparing a more centralized, patient-friendly information and support network
  • Continuing to offer opportunities for patients to participate in CCF’s annual conference and regional symposia.

The sites International Cholangiocarcinoma Patient Registry and Gather Your Health Data with Ciitizen are now available on CCF’s homepage on its website.

Ms Bachini encouraged patients to do their part to assist, accelerate, and support research into CCA, by taking a few minutes to join the patient registry through the category “Join the Patient Registry” under the “Patients” tab on their site.

Related Items

Hot Topics on Cholangiocarcinoma at the 2023 Cholangiocarcinoma Foundation Annual Conference
By Melinda Bachini; Juan W. Valle, MB ChB, MSc, FRCP
On April 14, 2023, we presented an overview of key abstracts on cholangiocarcinoma (CCA) presented at the 2023 Cholangiocarcinoma Foundation Annual Conference.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Durvalumab in Combination with Gemcitabine/Cisplatin in Advanced BTC (TOPAZ-1)
June/July 2022, Vol 3, No 2
A phase 3 study showed that the addition of cytotoxic chemotherapy to the PD-L1 inhibitor durvalumab was associated with promising antitumor activity as first-line treatment for patients with advanced biliary tract cancer.
Novel Approaches to Overcome FGFR Resistance
June/July 2022, Vol 3, No 2
In a Cholangiocarcinoma (CCA) Foundation meeting session, Dr Francesco Facchinetti from the Gustave Roussy Cancer Campus discussed novel approaches to overcome FGFR resistance in FGFR-altered CCA.
The Role of ctDNA in Promoting a Cure for CCA
June/July 2022, Vol 3, No 2
In a Cholangiocarcinoma (CCA) Foundation meeting session, Dr Zachariah H. Foda from the Johns Hopkins School of Medicine discussed the role of circulating tumor DNA in early detection and disease monitoring for CCA.
Deep Immune Profiling of Intrahepatic Cholangiocarcinoma
June/July 2022, Vol 3, No 2
At the Cholangiocarcinoma (CCA) Foundation meeting, Dr Mark Yarchoan from the Johns Hopkins School of Medicine presented his fellowship project focused on deciphering immune micro-environments in molecularly defined CCA subsets.
Case-Based Panel Discussion: Multidisciplinary Care of CCA
June/July 2022, Vol 3, No 2
At the 2022 annual meeting of the Cholangiocarcinoma (CCA) Foundation, a case-based panel discussion focused on multidisciplinary care of CCA.
Targeted Therapies on the Horizon for CCA
June/July 2022, Vol 3, No 2
Rachna T. Shroff, MD, MS, Chief, Section of Gastrointestinal Medical Oncology, University of Arizona Cancer Center, Tucson, reviewed promising clinical data regarding novel targeted therapies currently under clinical investigation for the treatment of cholangiocarcinoma.
Why We Need Correct ICD Coding for CCA
June/July 2022, Vol 3, No 2
At the 2022 Cholangiocarcinoma (CCA) Foundation annual meeting, Dr Shahid Khan, Clinical Senior Lecturer at Imperial College London, discussed the need for correct International Classification of Diseases coding for CCA.
Influence of the Microbiome in Cancer
June/July 2022, Vol 3, No 2
One session at the 2022 Cholangiocarcinoma Foundation annual meeting focused on the role of microbiome in the pathogenesis of hepatobiliary cancers.
Caring for a Loved One with CCA: A Son’s Perspective
June/July 2022, Vol 3, No 2
At the 2022 Cholangiocarcinoma (CCA) Foundation annual meeting, Ambuj Srivastava shared his experience as a current caregiver for his dad who was diagnosed with stage 2 extrahepatic CCA.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: